These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36964606)

  • 1. Therapeutic preference for Alzheimer's disease treatments: a discrete choice experiment with caregivers and neurologists.
    Dranitsaris G; Zhang Q; Mu L; Weyrer C; Drysdale E; Neumann P; Atri A; Monfared AAT
    Alzheimers Res Ther; 2023 Mar; 15(1):60. PubMed ID: 36964606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Preference for Alzheimer's Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors.
    Dranitsaris G; Zhang Q; Quill A; Mu L; Weyrer C; Dysdale E; Neumann P; Tahami Monfared AA
    Neurol Ther; 2023 Feb; 12(1):211-227. PubMed ID: 36422822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologists' preferences for device-aided therapy for advanced Parkinson's disease in Japan.
    Fujioka S; Mishima T; Yamazaki T; Bebrysz M; Nomoto M; Yamaguchi J; Fujimura K; Migita H; Aballéa S; Tsuboi Y
    Curr Med Res Opin; 2023 Jan; 39(1):91-104. PubMed ID: 36217768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
    Morel T; Aymé S; Cassiman D; Simoens S; Morgan M; Vandebroek M
    Orphanet J Rare Dis; 2016 May; 11(1):70. PubMed ID: 27225337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
    Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
    Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrete choice experiment for eliciting preference for health services for patients with ALS and their informal caregivers.
    Tobin K; Maguire S; Corr B; Normand C; Hardiman O; Galvin M
    BMC Health Serv Res; 2021 Mar; 21(1):213. PubMed ID: 33750360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
    Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
    Front Public Health; 2021; 9():653450. PubMed ID: 33842426
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies.
    Ettinger AB; Carter JA; Rajagopalan K
    Epilepsy Behav; 2018 Mar; 80():247-253. PubMed ID: 29433949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
    Yong C; Cambron-Mellott MJ; Seal B; Will O; Maculaitis MC; Clapp K; Mulvihill E; Cotarla I; Mehra R
    Patient Prefer Adherence; 2022; 16():123-135. PubMed ID: 35068928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
    Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
    Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
    Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
    Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making.
    Mansfield C; Bullok K; Fuhs JV; Tockhorn-Heidenreich A; Andrews JS; DiBenedetti D; Matthews BR; Darling JC; Sutphin J; Hauber B
    Patient; 2022 Sep; 15(5):551-564. PubMed ID: 35435572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
    Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
    J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Societal preferences for fertility treatment in Australia: a stated preference discrete choice experiment.
    Botha W; Donnolley N; Shanahan M; Norman RJ; Chambers GM
    J Med Econ; 2019 Jan; 22(1):95-107. PubMed ID: 30431385
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.